Giustozzi Michela, Vedovati Maria Cristina, Verso Melina, Scrucca Luca, Conti Serenella, Verdecchia Paolo, Bogliari Giulio, Pierpaoli Lucia, Agnelli Giancarlo, Becattini Cecilia
Internal Vascular and Emergency Medicine and Stroke Unit, University of Perugia, Perugia, Italy.
Statistics Division, Department of Economy, University of Perugia, Perugia, Italy.
Data Brief. 2019 Mar 1;23:103794. doi: 10.1016/j.dib.2019.103794. eCollection 2019 Apr.
The data presented in this article are related to the research article entitled "Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study" [1]. This article unveils original data of a cohort of 546 patients aged 90 years or older with non-valvular atrial fibrillation treated with oral anticoagulants. Here, we describe the time course of ischemic stroke and systemic embolism and of major bleeding according to the presence of outcome predictors and report the causes of permanent discontinuation and of death. Furthermore, we report data on the incidence of ischemic stroke and systemic embolism, of major bleeding, of permanent discontinuation and of all-cause death comparing i) oral anticoagulant naïve users vs. long-term oral anticoagulant users, ii) patients on anticoagulant therapy for less than 2 years (new users) vs. patients on anticoagulant therapy for more than 2 years. The material of this data article provides a better understanding on the use of oral anticoagulants in this fragile population and facilitates further critical analysis. Moreover, it aims at highlighting the importance of increasing knowledge in patients aged 90 years or older. These patients are often excluded from or under-represented in clinical trials and cohort studies.
本文所呈现的数据与题为《90岁及以上非瓣膜性心房颤动患者口服抗凝剂治疗:一项多中心观察性研究》的研究论文相关[1]。本文揭示了一组546例90岁及以上接受口服抗凝剂治疗的非瓣膜性心房颤动患者的原始数据。在此,我们根据结局预测因素的存在情况描述缺血性卒中和全身性栓塞以及大出血的时间进程,并报告永久停药和死亡的原因。此外,我们报告了缺血性卒中和全身性栓塞、大出血、永久停药以及全因死亡发生率的数据,比较了:i)未使用过口服抗凝剂的患者与长期口服抗凝剂的患者;ii)接受抗凝治疗少于2年的患者(新使用者)与接受抗凝治疗超过2年的患者。本数据文章的资料有助于更好地理解在这一脆弱人群中口服抗凝剂的使用情况,并促进进一步的批判性分析。此外,其旨在强调增加90岁及以上患者知识的重要性。这些患者在临床试验和队列研究中常常被排除在外或代表性不足。